Poznan

• A Open-label Study to Evaluate the Efficacy, Safety, Tolerability of HZN-825 in Patients with Diffuse Cutaneous Systemic Sclerosis Ended
  2023-509783-23-00 4 2023-02-24 Diffuse Cutaneous Systemic Sclerosis
• Phase 3 Study to Assess Efficacy and Safety of Batoclimab as Induction and Maintenance Therapy in Adult Participants with Generalized Myasth … Ended
  2024-512258-91-00 5 2023-02-03 Generalized Myasthenia Gravis (gMG)
• A study to learn how well the drug EDP-938 works and how safe it is for non-hospitalized Adults with Acute Respiratory Syncytial Virus Infec … Ended
  2024-513861-38-00 4 2023-02-02 Respiratory syncytial virus (RSV)
• A research study to see how well CagriSema helps people with type 2 diabetes and excess body weight lose weight Ended
  2023-506931-13-00 5 2023-01-30 Overweight and obesity and type 2 diabetes
• Dose ranging study of amlitelimab in adult participants with moderate-to-severe asthma Ended
  2024-510641-33-00 4 2023-01-17 Asthma
• Clinical study to show if Naronapride tablets are safe and efficient for treatment of delayed stomach emptying and to find the optimal dose. Ended
  2023-510195-31-00 4 2023-01-03 Idiopathic or Diabetic Gastroparesis
• A study to Evaluate AB308 in Combination with AB122 in Participants with Advanced Malignancies (ARC-12) Ended
  2024-511116-25-00 1 2022-12-13 Multiple Myeloma
• Pulmonary REsistance modification under treatment with Sacubitil/valsartaN in paTients with HeartFailure with reduced ejection fraction Ended
  2024-517975-19-00 6 2022-12-12 Heart Failure with reduced ejection fraction.
• A Phase 3 Study of Telitacicept for the Treatment of Moderately to Severely Active Systemic Lupus Erythematosus Ended
  2022-500445-24-00 5 2022-11-30 Moderately to Severely Active Systemic Lupus Erythematosus
• A study in people with systemic sclerosis to test whether BI 685509 has an effect on lung function and other systemic sclerosis symptoms Ended
  2022-500332-11-00 4 2022-11-25 systemic sclerosis
• A study to learn how well the study treatment asundexian works and how safe it is compared to apixaban to prevent stroke or systemic embolis … Ended
  2023-503794-38-00 5 2022-11-24 Prevention of stroke or systemic embolism in atrial fibrillation
• A study to test the safety of MK-1654 and how well MK-1654 works in healthy infants Ended
  2022-500350-42-01 10 2022-11-07 Prevention of RSV
• A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered Mosunetuzumab to Partici … Ended
  2023-509188-26-00 3 2022-10-27 Systemic Lupus Erythematosus (SLE)
• A clinical study conducted to evaluate the safety, efficacy and tolerability of a drug called liposomal annamycin administered with cytarabi … Ended
  2024-516388-10-00 9 2022-09-23 Acute Myeloid Leukemia
• A Randomized, Phase 2 Study of Pembrolizumab And Chemotherapy With or Without MK-4830 as Neoadjuvant Treatment for High-Grade Serous Ovarian … Ended
  2023-505005-16-00 4 2022-07-27 Primary peritoneal cancer/Fallopian tube cancer
• Open-label trial to check the safety and tolerability of RTX-GRT7039 injections for pain associated with osteoarthritis of the knee. Ended
  2024-515709-24-00 5 2022-07-26 Moderate to severe pain associated with Osteoarthritis of the knee
• Tezepelumab Efficacy and Safety in Reducing Oral Corticosteroid Use in Adults with Oral Corticosteroid Dependent Asthma Ended
  2023-504648-33-00 5 2022-07-19 Oral Corticosteroid Dependent Asthma
• Inhaled Imatinib Pulmonary Arterial Hypertension Clinical Trial (IMPAHCT) or A Phase 2b/3, Randomized, Controlled, 24-week Dose Ranging and … Ended
  2023-508734-34-00 10 2022-06-30 Pulmonary Arterial Hypertension (PAH)
• A Phase 1 open-label, first-in-human, multi-center, dose escalation and dose expansion study of CLN-619 administered alone or in combination … Ended
  2024-511744-27-00 1 2022-06-27 Solid tumors, Non-Small Cell Lung Cancer, Cervical Cancer, Endometrial
• Adjusted brodalumab dose compared with standard brodalumab dose in subjects with moderate-to-severe plaque psoriasis and ≥120 kg body weight … Ended
  2023-509668-11-00 6 2022-06-15 Moderate-to-severe plaque psoriasis and a body weight ≥120 kg.
• IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma Ended
  2024-511996-13-00 5 2022-05-11 Previously untreated, unresectable, or metastatic melanoma
• The WILLOW study with enpatoran in SLE and CLE (SCLE and/or DLE) Ended
  2024-510872-18-00 4 2022-05-09 Systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (
• This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study where subjects with non-pharmacologically treated acromeg … Ended
  2024-511924-15-00 5 2022-04-29 Acromegaly
• A study comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF5993 With the Fixed Dose Dual Combination CHF153 … Ended
  2023-510172-31-00 5 2022-04-22 Chronic obstructive pulmonary disease (COPD)

Showing 793–816 of 914 trials